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Abstract
Engraftment of IL-6 deficient donor into wild-type recipient could significantly improve allograft survival through T cell
lineage particularly regulatory T cells (Tregs) in non-sensitized transplant host. However, its effect on innate immune
responses remains uncertain. Our data revealed that donor IL-6 deficiency significantly increased infiltration of two
subsets of MDSCs (CD11b+Gr1+myeloid-derived suppressor cells), CD11b+Gr1-low and CD11b+Gr1-int with strong
immunosuppression activity in the transplanted graft. It resulted in a dramatic increase of CD11b+Gr1-low frequency
and a significant decrease of the frequency of CD11b+Gr1-high and CD4-CD8-NK1.1+ cells in the recipient’s spleen.
Unexpectedly, donor IL-6 deficiency could not significantly reduce macrophage frequency irrespective of in the host’s
spleen or graft. Taken together, suppression of innate immune effector cells and enhanced activity of regulatory
MDSCs contributed to tolerance induction by blockade of IL-6 signaling pathway. The unveiled novel mechanism of
targeting IL-6 might shed light on clinical therapeutic application in preventing accelerated allograft rejection for those
pre-sensitized transplant recipients.
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Introduction
Interleukin-6 (IL-6) as a pleiotropic cytokine can be produced
by various tissues particularly proinflammatory cell types and
formed in local cytokine milieu. It is capable of orchestrating
cellular differentiation, affecting early graft function recovery [1],
and disrupting transplant tolerance induction [2,3]. IL-6
produced from injured allograft vessels could promote the
magnitude of intimal expansion and allogeneic T cell infiltration
through suppressing an increase of CD161+ regulatory T cells
[4]. The multifaceted activities of IL-6 can be characterized by
inhibition of Th1 response, impairment of suppressive function
of regulatory T cells (Tregs), and promotion of Th2 and Th17
lineage development, directing against transplant tissue [5-7].
IL-6 amplifier and NF-kB-triggered positive feedback for IL-6
mediate in vitro hyperinduction of chemokine ligand 2 (CCL2)
by IFN-γ in type 1 collagen cells, contributing to allogeneic
responses and graft rejection [8].Therefore, it was observed
that donor graft-derived but not recipient source IL-6 becomes
a systemic danger signal impairing constitutive immune
suppression. Accumulating experimental and clinical evidences
revealed that intragraft IL-6 gene expression level is closely
associated with chronic [9] and acute graft rejection [3,7].
Elevation of urinary IL-6 concentration and serum IL-6R (IL-6
receptor) level was reported to be a suitable biomarker for
predicting an early acute transplant rejection episode [10].
Conversely, donor IL-6 deficiency prolongs allograft survival via
the presence of regulatory CD25+ T cells [3]. Neutralization of
IL-6 can reduce T cell infiltration and decrease Th17 markers
[4], rescuing early graft function [1] and significantly prolonging
allograft survival [2,3,7].
Indeed, not only adaptive but innate immune cells are
required for acute or chronic rejection in various transplant
settings [11]. A recent study reported that TLR4/TRIF pathway
contributes to allogeneic bone marrow cell rejection dependent
on innate immune cells including F4/80+ (macrophages) or
NK1.1+ cells (NK cells), causing a significant production of
proinflammatory cytokine IL-6 and TRIF relevant chemokine
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MCP-1 [12]. During transplantation surgery the mechanical and
ischemia-reperfusion injuries are inevitable, which causes
microbial productions or endogenous pro-inflammatory ligands
[11]. Thereafter, necrotic lysates released from graft can trigger
higher inflammatory responses in dendritic cells (DCs) and
natural killer cells, resulting in a remarkable production of
inflammatory mediators including TNF-α and IL-6 in a MyD88-
dependent manner, an insusceptibility of alloreactive T cells to
suppression by CD4+CD25+ regulatory T cells (Tregs), and an
initiation of T-cell immunoresponses against graft [2,11]. By
contrast, absence of both IL-6 and TNF-α can result in
permanent acceptance of allograft [2].
Although impact of IL-6 on adaptive immune responses was
described in different transplant models [2,3,7], its specific
contribution to the process of innate immune responses
remains to be elucidated. To this end, we utilized a pre-
sensitized transplant model for studying the effect of IL-6 on
innate immune responses. A deeper understanding of the role
of IL-6 during transplantation may pave the way to a more




Eight-twelve week male inbred mice were obtained from the
Jackson Laboratories (JAX, Bar Harbor, ME) including wild-
type C57BL/6 (B6; H-2b; Stock No. 000664), BALB/c (B/c; H-2d;
Stock No. 000651), and B6:129S2-IL-6tm1Kopf/J (IL-6KO; H-2b;
Stock No. 002650). The mice were housed under pathogen-
free conditions at the Center for Life Science (Boston, MA).
Animal studies were approved by the Institutional Animal Care
and Use Committee (IACUC) at Beth Israel Deaconess Medical
Center. Allogeneic heterotopic heart transplantations (HTx)
were performed using BALB/c donors and C57BL/6 recipients.
Vascularized heterotopic heart transplantation
Abdominal heterotopic heart transplantation was performed
using standard microsurgical techniques as previously
described [13,14]. Briefly, the mice were anesthetized with an
intraperitoneal injection of a mixture of ketamine (60 mg/kg)
and xylazine (10 mg/kg). The pulmonary artery and the
ascending aorta of donor were anastomosed end-to-side to the
recipient’s inferior vena cava (IVC) and the abdominal aorta.
Graft function was daily monitored by observation of donor
heartbeat palpation. The happening of rejection was judged
when heart beating was completely ceased and later confirmed
by histology. The cardiac grafts that did not function at day 1
post-transplantation were not included.
Experimental groups are shown in Table 1. Briefly, to test the
role of donor IL-6 cytokine in the non-sensitized transplant
settings, IL-6 deficient (knockout with C57BL/6 background)
mice were used as donor and Balb/c mice acted as recipients
(G1). These recipients were treated an isotype control iso-IgG
as controls. To prove involvement of Tregs for the protective
role of donor IL-6 deficiency, anti-CD25 monoclonal depleting
antibodies (mAb) (0.25 mg, clone PC61, BD Pharmingen) were
intraperitoneally applied 3 days before transplantation for
aforementioned transplant recipients (G2). Tregs depletion was
confirmed by an analysis of peripheral CD4+CD25+ cells
frequency at day -3 (pre-administration of anti-CD25 mAb), day
0 (transplant surgery), day 3, and day 9 post-transplant via flow
cytometry (Figure 1). In addition, allogeneic (G3) and
syngeneic (G4) transplantations were performed as control
groups. These four groups (G1-G4) were established to
generate allograft survival curves. Furthermore, to investigate
the impact of donor IL-6 deficiency on innate immune system,
PCI-mediated injury in the pre-sensitized transplant settings
was utilized for our study based on our previous researches
[15]. C57BL/6 recipients pre-sensitized by Balb/c skins at
transplant day -7 were engrafted with wild-type C57BL/6 hearts
with PCI (7.0±0.5 hours, G5) or IL-6 deficient (IL-6KO)
C57BL/6 hearts with PCI (6.5±0.8 hours, G6). This PCI time
can partially cause cardiac graft injury rather than heart-beat
failure (unpublished data).
Reagents and antibodies
Immunofluorescence analysis and mAbs.  Harvested
spleen and heart cells were directly labeled with fluorescently
conjugated monoclonal antibodies (mAbs). All mAbs used for
cell surface staining were purchased from BioLegend (San
Diego, CA). For FACS staining, anti–mouse CD4 (Clone
H129.19, Catalogue No. 130308) FITC-conjugated mAb, anti–
mouse CD8a (Clone 53–6.7, Catalogue No. 100701) PE-
conjugated mAb, Alexa Fluor® 700-conjugated anti-mouse
Gr-1/Ly-6G (Clone RB6-8C5, Catalogue No. 108421) mAb, and
the pacific blue-conjugated anti–mouse CD11b (clone M1/70,
Catalogue No. 101223) mAb were used to label live T cells. All
samples were acquired using an LSRII (BD Biosciences,
Mountain View, CA). Data was analyzed using FlowJo 7.5
software (Tree Star, Ashland, OR), as we reported before [16].
The analysis gate was set on the side and forward scatters to
eliminate debris and dead cells cell.
Isolation of graft-infiltrating leukocytes
The heart grafts were harvested, minced and then incubated
in Roswell Park Memorial Institute (RPMI) 1640 medium
Table 1. Displays design of experimental groups of non- or
pre-sensitization and the treatment characteristics.
Group n
Skin for
sensitization Donor for HTx
PC61 (0.25mg,
i.v.) PCI (hrs)
G1 7(5) ξ No IL-6KO No No
G2 9(5) ξ No IL-6KO Yes No
G3 7(5) ξ No C57BL/6 No No
G4 6(6) ξ No BALB/c No No
G5 3 BALB/c C57BL/6 No 7.0±0.5
G6 4 BALB/c IL-6KO No 6.5±0.8
ξ. The number in the parenthesis represents amount of transplant surgeries for
survival curves among total surgeries (n).
doi: 10.1371/journal.pone.0077559.t001
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containing 0.5 mg/mL collagenase IV (Sigma-Aldrich, St. Louis,
MO, USA) for 30 min at 37°C in the shaker. Tissue debris was
carefully removed with 70-µm cell strainer. After washing twice,
viable mononuclear cells were separated by Ficoll density
gradient centrifugation. The cells at the interface were isolated
and washed thrice with RPMI 1640 medium supplemented with
10% FBS and then subjected to either fluorescence-activated
cell sorting (FACS) staining.
Histology and Immunohistochemical Analysis
Cardiac grafts were harvested at day 9 post-transplantation.
Heart specimens were fixed in 10% paraformaldehyde and
then embedded in paraffin. Tissue was sectioned at 5µm-
thickness. These sections were stained with hematoxylin and
eosin (H&E) and assessed by light microscopy to determine
the extent of cellular infiltration.
Frozen heart graft specimen were sectioned at 5-μm-
thickness and immunohistochemistry was performed using an
avidin-biotin-peroxidase technique (Vector Laboratories, Inc,
Burlingame, CA), with ImmPACT DAB Chromogen. Heart
sections were blocked with goat serum and then labeled with
an anti- Mouse Ly-6G (Gr-1, Clone IA8, Catalogue No.
551495), a monoclonal antibody (eBiosience, San Diego, CA),
which recognizes neutrophils. Specimen sections were
incubated using the Avidin-Biotin Complex Solution, Vectastain
Elite ABC kit (Vector Laboratories, Inc, Burlingame, CA).
ImmPACT DAB Chromogen was applied and subsequently
counter-stained with Harris hematoxylin.
Statistical analysis
Allograft survival curves were generated by using the
Kaplan-Meier method. All data were analyzed using the
statistical software GraphPad Prism version 5.0 (GraphPad
Software, San Diego, CA). The FACS data between groups
Figure 1.  Administration of anti-CD25 mAb (PC61)
depleted CD4+CD25+Foxp3+ cells (n=2).  Peripheral blood
CD4+CD25+Foxp3+ T cells was analyzed through flow
cytometry at day -3 (pre-administration of anti-CD25
monoclonal antibody), day 0 (transplant surgery), day 3, and
day 9 post-transplant surgery. Administration of anti-CD25mAb
3 days before transplant surgery resulted in a continuous
decrease of frequency of peripheral CD4+CD25+Foxp3+ T
cells (12.4% on day -3, 2.78% on day 0, 0.64% on day 3). On
day 9, the frequency of peripheral CD4+CD25+Foxp3+ T cells
reactively increased owing to acute rejection event.
doi: 10.1371/journal.pone.0077559.g001
were determined by a student T-test. The difference of graft
survival between different groups was compared by both log-
rank (Mantel-Cox Test) and Gehan-Breslow-Wilcoxon Test. A
p-value of .05 was determined as statistical significance. The
FACS data were expressed as mean ± SD.
Results
Prolonged Survival of IL-6 Deficient Heart Allografts
Previously, various experimental studies demonstrated a
critical role of donor IL-6, which mainly originated from the
donor allograft tissue and could impair allograft survival [3].
This data was supported by our present studies, in which
utilization of IL-6 deficient donor caused a prolonged allograft
survival. The mean survival time (MST) of IL-6-/- heart grafts in
the wild-type BALB/c recipients (IL-6KO B/c) was significantly
increased (19.8±2.8 days) compared to that of allogeneic grafts
(B6 B/c) (MST=8.0±1.2 days; Mantel-Cox Test, p=0.0012;
Gehan-Breslow-Wilcoxon Test, p=0.0031) (Figure 2).
However, additional use of anti-CD25 mAb (PC61) to those
IL-6-/- heart grafts (IL-6-/-BALB/c) pronouncedly shortened
graft survival equivalent to allogeneic control group (B6
BALB/c) (Figure 2). An increase of frequency of peripheral
CD4+CD25+Foxp3+ regulatory T cells (Figure 1) was caused
owing to acute rejection event, accounting for a protective
reactivity of recipient in the settings of strong effect of effector
cells. It demonstrated that depletion of Tregs resulted in the
poor transplant outcome despite lack of donor IL-6 cytokine,
indicating that regulatory T cells were involved in the protective
effect of donor IL-6 deficiency. Afterwards, pathological and
immunohistochemical analysis were performed to further
validate this findings. As a result, mild subepicardiac graft
infiltrating leukocytes (GILs) particularly reduction of Gr1+
neutrophils were observed, while donor IL-6 deficiency
combined with Tregs depletion caused a severe infiltration of
leukocytes and Gr1+ neutrophils and cardiac structure
destruction, accounting for acute rejection events on day 9
post-transplantation (Figure 3A and 3B).
Characterization of innate immune cells in PCI-
mediated injury in the pre-sensitized transplant host
engrafted with IL-6 deficient donor
To clearly identify the impact of PCI on allograft in the
sensitized recipients, we dissected the process of accelerated
transplantation and utilized syngeneic cardiac transplantation
with PCI after recipients were pre-sensitized by fully MHC-
mismatched skin. Based on the evident effect of IL-6
abrogation in the non-sensitized transplant model, we
attempted to test whether lack of intragraft IL-6 cytokine could
cause any significant alteration of innate immune response in
the pre-sensitized transplant host’s spleen. Based on
aforementioned data on the critical role of Tregs in the
transplantation, we firstly tested non-specific innate
immunoregulatoy cells, myeloid-derived suppressor cells
(MDSCs), which have been thoroughly studied in our previous
research. MDSCs can be sub-grouped into three different
subsets, CD11b+Gr1-low, CD11b+Gr1-int, and CD11b+Gr1-high
with distinct immunoregulatory effect. Therefore, we tried to
Critical Role of IL-6 in Transplantation
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characterize MDSCs subsets, macrophage, NK1.1+ cells in the
spleen of wild-type donor + PCI (G5) and IL-6 deficient donor +
PCI (G6) by flow cytometry analysis (Table 1). As a result, our
studies revealed that donor IL-6 deficiency caused mild
reduction of macrophage (F4/80+) frequency (G5 vs. G6:
p=0.3), a dramatic increase of CD11b+Gr1-low frequency
(p=0.0021) and a significant decrease of CD11b+Gr1-high
Figure 2.  Kaplan-Meier cardiac graft survival curve.  Heterotopic abdominal heart transplantation was performed by using
standard procedure. All transplanted mice were monitored every day until graft rejection, defined as the cessation of palpable
cardiac activity. Although only three symbols of “triangle” are observed for group (WT B6B/c), two grafts survived for 7 days and two
grafts survived for 8 days. It implies that each “triangle” on day 7 (60% remained to survive on day 7) and day 8 (20% remained to
survive on day 8) represents two grafts. Graft survival of the allogeneic control group (C57BL/6BALB/c, n=5) is equivalent to IL-6
deficiency donor graft (IL-6KOBALB/c) treated with anti-CD25 mAb (n=5) (Mantel-Cox Test, p=0.17; Gehan-Breslow-Wilcoxon Test,
p=0.28), whereas IL-6 deficiency donor graft survival (IL-6KOBALB/c) treated with iso-IgG (n=5) was significantly prolonged
(Mantel-Cox Test, p=0.012; Gehan-Breslow-Wilcoxon Test, p=0.0031) in comparison to allogeneic control group.
doi: 10.1371/journal.pone.0077559.g002
Figure 3.  Graft histology and immunohistochemical analysis of grafts.  (A) The heart transplanted recipients were sacrificed at
day 9 after surgery. Allogeneic grafts were harvested, stained with H&E to assess inflammation and lymphocytes infiltration between
different groups under microscope, as described in the Methods section. The figure shows that a mild leukocytes infiltration was
observed in the IL-6 deficient donors (G1) (n=2), while a pronouncedly infiltration of leukocytes and preserved cardiac architecture
were observed in the subepicardial area of the IL-6KO grafts treated by anti-CD25 mAb (PC61) (G2) (n=2) and wild-type allografts
(G3) (n=2) without any treatment. (B) Grafts specimens harvested at day 9 post-transplant were snap-frozen into Tissue Tec and
stained for Gr-1 protein as described in the Materials and Methods section. Immunohistochemical sections showed that depletion of
Treg cells using anti-CD25 mAb (PC61) remarkably caused an infiltration of Gr-1+ cells in the IL-6 deficient grafts, which is similar to
acutely rejected wild-type hearts. A mild subepicardial Gr-1+ cells infiltration was found within IL-6KO grafts without any treatment.
Original magnification ╳ 40.
doi: 10.1371/journal.pone.0077559.g003
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 (p=0.00015) and CD4-CD8-NK1.1+ cells (p=0.0017) frequency
in the recipient’s spleen (Figure 4).
Significant accumulation of CD11b+Gr1-low and CD11b
+Gr1-int MDSCs within IL-6 deficient graft.  To detect whether
donor IL-6 deficiency affects two important subsets of MDSCs,
CD11b+Gr1-low and CD11b+Gr1-int with strong
immunosuppression activities, the pre-sensitized transplanted
grafts with PCI including IL-6-deficiency and wild-type were
Figure 4.  (A) The frequency of MDSCs, CD4-CD8-NK1.1+,
F4/80+ cells in the spleen of the transplant
recipient.  These innate immune cells in the spleens were
collected for fluorochrome-labeling and subject to FACS
analysis on day 3 after transplant. (B) Statistical analysis was
performed for the groups G5 (n=3) and G6 (n=4). *p<0.05,
**p<0.01.
doi: 10.1371/journal.pone.0077559.g004
harvested. The infiltrated leukocytes within graft were isolated
and subject to cytometry analysis. The findings revealed that
donor IL-6 deficiency did not remarkably suppress infiltration of
macrophage within graft (p=0.3), while it caused a significant
increase of intragraft CD11b+Gr1-low (p=0.00001) and CD11b
+Gr1-int frequencies (p=0.032) in the early stage (Figure 5).
Figure 5.  (A) The frequency of MDSCs, CD4-CD8-
NK1.1+, F4/80+ cells within cardiac graft of the transplant
recipient. Graft-infiltrating these innate immune cells were
collected for fluorochrome-labeling and subject to FACS
analysis on day 3 after transplant. (B) Statistical analysis
was performed for the groups G5 (n=3) and G6 (n=4).
*p<0.05, **p<0.01.  
doi: 10.1371/journal.pone.0077559.g005
Critical Role of IL-6 in Transplantation
PLOS ONE | www.plosone.org 5 October 2013 | Volume 8 | Issue 10 | e77559
Discussion
The presensitized PCI-mediated transplant model was
selected for two reasons. First, prior to empirical transplant
surgery a considerable amount of transplant recipients have
undergone previous failed transplants, multiple blood
transfusions, ventricular assist device placement, or
pregnancies, more likely to endanger hosts to alloantigen-
sensitization situation. Our previous novel findings revealed
that pre-sensitized immune condition of recipient can
exaggerate PCI-mediated injury of heart grafts. Second, owing
to scarcity transplant organ much effort has been made to
utilize remote donors, leading to a prolongation of cold-
ischemic time during organ transportation.
Allogeneic immune responses directing allograft are the main
obstacle to transplant tolerance induction [7]. Past studies on
graft acceptance and survival mainly focus on adaptive
immune cells including B and T cells, and their long-lasting
immunological memory cells [17]. The fact that IL-6 contributes
to numerous adaptive immunologic effects associated with
transplant rejection has been fully described [1-3,7-9]. Herein,
we attempted to appreciate the critical role of donor IL-6
deficiency in innate alloimmunity under pre-sensitized PCI-
mediated injury condition.
Numerous cell types accounting for alloimmune responses
can culminate in heart graft rejection [7]. Evidence has shown
that allogeneic immune responses are characterized by
monocytes/macrophages and neutrophils infiltration within
grafts. Monocyte is able to infiltrate allograft within 20 hours,
rapidly differentiate into mature dendritic cells (DCs), and elicit
immunoresponse as donor and recipient differs at non-MHC
loci. In lung transplantation monocyte prior to neutrophil
migrates to graft in a CCR2-dependent manner [18,19].
Adoptive transfer of monocytes from alloimmunized host can
confer allorecognition to naïve host [18]. Furthermore, it was
found that at day 3 posttransplantation a vast majority of
intragraft DCs are derived from recipient’s monocytes [18].
With respect to NK cell, it can express both activating and
inhibitory receptors despite the missing-self theory, lack of self-
MHC molecules on cell surface [18]. Activated NK cell can kill
target cells via lysis and then bear memory property. In
addition, NK cell is capable of shaping adaptive immune
responses through producing cytokines, which orchestrate B
and T cell response [20]. Studies have shown that NK cells are
necessary and sufficient for host to chronically reject allograft
[21,22]. Nevertheless, depletion of NK cells in wildtype mice
cannot effectively attenuate acute rejection even in
combination with T cells depletion [22]. Dr. Lakkis FG et al.
revealed that NK cells are capable of downregulating the
homeostatic proliferation of CD8+ T cells under lymphopenic
conditions, delaying allograft rejection [23]. Therefore, it was
proposed that NK cells do not possess a critical link between
innate and adaptive immune responses under transplant
condition [18].
Therefore, our present study tested the role of those innate
immune cells including macrophage, NK1.1+ cell, and MDSCs
subsets in the setting of PCI-mediated injury in the pre-
sensitized transplant host. The findings manifested that donor
IL-6 deficiency mounted a weaker immune response in such
pre-sensitized transplant recipient. At day 3 post-
transplantation macrophage frequency in the graft (Figure 4B)
and spleen (Figure 5B) remained decreased despite no
significance. In addition, donor IL-6 deficiency resulted in a
significant decrease of CD4-CD8-NK1.1+ cells frequency in the
recipient’s spleen. MDSCs featured as innate
immunoregulatory cells, are able to inhibit allogeneic T cells
proliferation and allorecognition (submitted to Cell
Transplantation, manuscript No. CT-1098). Thereafter, it is
reasonable to explain that remarkable infiltration of two main
subsets of MDSCs, CD11b+Gr1-low and CD11b+Gr1-int was
observed within donor IL-6 deficient graft. A dramatic increase
of CD11b+Gr1-low frequency and a significant decrease of
CD11b+Gr1-high frequency were found in the recipient’s spleen.
By far, it is well-studied that heart is the main source
producing cytokine IL-6 [3]. The inflammatory process of
transplantation followed by ischemia/reperfusion can cause
disturbance of mitochondria, and DNA escaping from flamed
heart [24]. Any mitochondrial DNA escaping the degradation
might bind to TLR9, capable of inducing cardiomyocytes to
produce IL-1β and IL-6 [25]. In a setting of CD8+ cell-dominant
rejection process, blockade of IL-6 could delay the onset of
acute rejection, prevent graft infiltration and reverse the ratio of
Th1/Th2 in host, while in the setting of CD4+ cell-dominant
graft rejection, blockade of IL-6 could significantly prolong graft
survival associated with reduced graft infiltration, altered Th1
responses, and inhibited production of serum alloantibody [7].
Nevertheless, the specific pathway of IL-6 toward triggering
allogeneic innate immunoreponses remains unclear particularly
the role of regulatory innate immune cells, MDSCs and further
investigations are required to clarify the details of underlying
molecular mechanisms.
Taken together, our present study revealed that blockade of
IL-6 signaling pathway suppressed innate immune effector
cells in large measure and enhanced activity of regulatory
MDSCs. This unveiled novel mechanism of targeting IL-6 might
shed light on clinical therapeutic application in preventing
accelerated allograft rejection for those pre-sensitized
transplant recipients.
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